scholarly journals How much is a coin worth: acute pancreatitis, suspected pancreatic cancer, and a Whipple surgery caused by ingestion of a coin?

2021 ◽  
Vol 16 (4) ◽  
pp. 390-391
Author(s):  
Ege Altan ◽  
Taylan Kav
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis

More Than 9-Times Increased Risk for Pancreatic Cancer Among Patients With Acute Pancreatitis in Chinese Population

Pancreas ◽  
2012 ◽  
Vol 41 (1) ◽  
pp. 142-146 ◽  
Author(s):  
Shiu-Dong Chung ◽  
Kuan-Yang Chen ◽  
Sudha Xirasagar ◽  
Ming-Chieh Tsai ◽  
Herng-Ching Lin
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chinese Population ◽  
Increased Risk

Determination of Plasma Glycoprotein 2 Levels in Patients With Pancreatic Disease

2004 ◽  
Vol 128 (6) ◽  
pp. 668-674 ◽  
Author(s):  
Ying Hao ◽  
Jing Wang ◽  
Ningguo Feng ◽  
Anson W. Lowe
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Tertiary Care ◽  
Pancreatic Disease ◽  
Pancreatic Acinar Cell ◽  
Enzyme Linked Immunosorbent Assay ◽  
Assay Sensitivity ◽  
Acute And Chronic Pancreatitis

Abstract Context.—Blood tests possessing higher diagnostic accuracy are needed for all the major pancreatic diseases. Glycoprotein 2 (GP2) is a protein that is specifically expressed by the pancreatic acinar cell and that has previously shown promise as a diagnostic marker in animal models of acute pancreatitis. Objective.—This study describes the development of an assay for GP2, followed by the determination of plasma GP2 levels in patients with acute pancreatitis, chronic pancreatitis, and pancreatic cancer. Design.—Rabbit polyclonal antisera and mouse monoclonal antibodies were generated against human GP2 and used to develop an enzyme-linked immunosorbent assay. The assay was tested in patients with an admitting diagnosis of pancreatic disease at 2 tertiary care facilities. The diagnosis of acute or chronic pancreatitis and pancreatic cancer was determined using previously established criteria that incorporated symptoms, radiology, pathology, and serology. Plasma GP2 levels were determined in 31 patients with acute pancreatitis, 16 patients with chronic pancreatitis, 36 patients with pancreatic cancer, and 143 control subjects without pancreatic disease. Amylase and lipase levels were also determined in patients with acute pancreatitis. Results.—The GP2 assay's sensitivity values were 0.94 for acute pancreatitis, 0.81 for chronic pancreatitis, and 0.58 for pancreatic cancer, which were greater than the 0.71 for acute pancreatitis and 0.43 for chronic pancreatitis (P = .02) observed for amylase. The lipase assay sensitivity for acute pancreatitis was 0.66. The accuracy of the GP2 assay was greater than that of the amylase or lipase assays for acute pancreatitis (GP2 vs lipase, P = .004; GP2 vs amylase, P = .003) when analyzed using receiver operator characteristic curves. When daily serial blood samples were obtained for 13 patients with acute pancreatitis, GP2 levels remained abnormally elevated for at least 1 day longer than the amylase or lipase levels. Conclusion.—The GP2 assay is a useful new marker for acute and chronic pancreatitis.

Pancreatic disease

2011 ◽  
pp. 611-618
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Chronic Pancreatitis ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Pancreatic Enzyme ◽  
Pancreatic Disease ◽  
Enzyme Replacement ◽  
Pancreatic Enzyme Replacement Therapy ◽  
Pancreatic Disorders

Pancreatic disorders 612 Pancreatic enzyme replacement therapy 616 See Table 27.1. The major pancreatic disorders include pancreatitis and pancreatic cancer. Pancreatitis results from the auto-digestion of the pancreas by activated pancreatic enzymes. It can be categorized as: • Chronic pancreatitis (CP). • Acute pancreatitis: •...

scholarly journals Polyphenols as Possible Agents for Pancreatic Diseases

Antioxidants ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 547
Author(s):  
Uroš Gašić ◽  
Ivanka Ćirić ◽  
Tomislav Pejčić ◽  
Dejan Radenković ◽  
Vladimir Djordjević ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Early Diagnosis ◽  
Pancreatic Disease ◽  
Biologically Active ◽  
Cytostatic Agents ◽  
Inhibitory Effects ◽  
Pancreatic Diseases ◽  
Anticancer Effects ◽  
Significant Data

Pancreatic cancer (PC) is very aggressive and it is estimated that it kills nearly 50% of patients within the first six months. The lack of symptoms specific to this disease prevents early diagnosis and treatment. Today, gemcitabine alone or in combination with other cytostatic agents such as cisplatin (Cis), 5-fluorouracil (5-FU), irinotecan, capecitabine, or oxaliplatin (Oxa) is used in conventional therapy. Outgoing literature provides data on the use of polyphenols, biologically active compounds, in the treatment of pancreatic cancer and the prevention of acute pancreatitis. Therefore, the first part of this review gives a brief overview of the state of pancreatic disease as well as the procedures for its treatment. The second part provides a detailed overview of the research regarding the anticancer effects of both pure polyphenols and their plant extracts. The results regarding the antiproliferative, antimetastatic, as well as inhibitory effects of polyphenols against PC cell lines as well as the prevention of acute pancreatitis are presented in detail. Finally, particular emphasis is given to the polyphenolic profiles of apples, berries, cherries, sour cherries, and grapes, given the fact that these fruits are rich in polyphenols and anthocyanins. Polyphenolic profiles, the content of individual polyphenols, and their relationships are discussed. Based on this, significant data can be obtained regarding the amount of fruit that should be consumed daily to achieve a therapeutic effect.

Carboxypeptidase a activity in pancreatic cancer and acute pancreatitis

1998 ◽  
Vol 114 ◽  
pp. A1425 ◽  
Author(s):  
P. Shamamian ◽  
S. Marcus ◽  
E. Deutsch ◽  
T. Maldonado ◽  
A. Liu ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Carboxypeptidase A

The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer

2016 ◽  
Vol 45 (4) ◽  
pp. 625-637 ◽  
Author(s):  
Zobeida Cruz-Monserrate ◽  
Darwin L. Conwell ◽  
Somashekar G. Krishna
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Gallstone Disease ◽  
The Impact

scholarly journals Consequences of COVID-19 for the Pancreas

2022 ◽  
Vol 23 (2) ◽  
pp. 864
Author(s):  
Urszula Abramczyk ◽  
Maciej Nowaczyński ◽  
Adam Słomczyński ◽  
Piotr Wojnicz ◽  
Piotr Zatyka ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Molecular Mechanisms ◽  
Multiple Organ ◽  
Pancreatic Function ◽  
Multiple Organ Dysfunction ◽  
Major Health ◽  
Growing Body ◽  
Adults And Children ◽  
Pancreatic Dysfunction

Although coronavirus disease 2019 (COVID-19)-related major health consequences involve the lungs, a growing body of evidence indicates that COVID-19 is not inert to the pancreas either. This review presents a summary of the molecular mechanisms involved in the development of pancreatic dysfunction during the course of COVID-19, the comparison of the effects of non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pancreatic function, and a summary of how drugs used in COVID-19 treatment may affect this organ. It appears that diabetes is not only a condition that predisposes a patient to suffer from more severe COVID-19, but it may also develop as a consequence of infection with this virus. Some SARS-CoV-2 inpatients experience acute pancreatitis due to direct infection of the tissue with the virus or due to systemic multiple organ dysfunction syndrome (MODS) accompanied by elevated levels of amylase and lipase. There are also reports that reveal a relationship between the development and treatment of pancreatic cancer and SARS-CoV-2 infection. It has been postulated that evaluation of pancreatic function should be increased in post-COVID-19 patients, both adults and children.

scholarly journals Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Yongjian Wen ◽  
Wenhao Cai ◽  
Jingyu Yang ◽  
Xianghui Fu ◽  
Lohitha Putha ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Acute Pancreatitis ◽  
Signaling Pathways ◽  
Migration Inhibitory Factor ◽  
Chemokine Receptors ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Great Promise ◽  
Macrophage Migration

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine implicated in the pathogenesis of inflammation and cancer. It is produced by various cells and circulating MIF has been identified as a biomarker for a range of diseases. Extracellular MIF mainly binds to the cluster of differentiation 74 (CD74)/CD44 to activate downstream signaling pathways. These in turn activate immune responses, enhance inflammation and can promote cancer cell proliferation and invasion. Extracellular MIF also binds to the C-X-C chemokine receptors cooperating with or without CD74 to activate chemokine response. Intracellular MIF is involved in Toll-like receptor and inflammasome-mediated inflammatory response. Pharmacological inhibition of MIF has been shown to hold great promise in treating inflammatory diseases and cancer, including small molecule MIF inhibitors targeting the tautomerase active site of MIF and antibodies that neutralize MIF. In the current review, we discuss the role of MIF signaling pathways in inflammation and cancer and summarize the recent advances of the role of MIF in experimental and clinical exocrine pancreatic diseases. We expect to provide insights into clinical translation of MIF antagonism as a strategy for treating acute pancreatitis and pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document